Compare HOG & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOG | TLX |
|---|---|---|
| Founded | 1903 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | HOG | TLX |
|---|---|---|
| Price | $21.61 | $9.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $28.00 | $21.00 |
| AVG Volume (30 Days) | ★ 2.6M | 108.9K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.04 | 0.04 |
| Revenue | ★ $4,664,627,000.00 | $664,225,558.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | ★ $5.34 | $284.97 |
| Revenue Growth | N/A | ★ 55.35 |
| 52 Week Low | $20.45 | $8.76 |
| 52 Week High | $33.59 | $30.36 |
| Indicator | HOG | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 30.15 | 38.74 |
| Support Level | $21.82 | $9.37 |
| Resistance Level | $22.77 | $10.03 |
| Average True Range (ATR) | 0.77 | 0.25 |
| MACD | -0.12 | -0.00 |
| Stochastic Oscillator | 0.73 | 7.65 |
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring segments, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 37% of the heavyweight domestic market in 2024.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.